Meeting NewsVideo

Real-world patient study confirms Mavyret efficacy for HCV

PARIS — Results from a real-world cohort of patients with hepatitis C treated with Mavyret showed a sustained virologic response of 97%, according to an exclusive interview with Thomas Berg, MD, at the International Liver Congress.

“What we observed in our cohort over the year was that we have newly diagnosed patients,” Berg, from the University Hospital Leipzig in Germany, told Healio Gastroenterology and Liver Disease. “Most of them had probably drug-induced transmission of hepatitis C virus, mild disease, and most patients with more advanced disease or with treatment experience were already being treated in our country.”

To date, Berg and colleagues have enrolled 866 patients with HCV and 638 of those have begun treatment with Mavyret (glecaprevir/pibrentasvir, AbbVie). In his presentation, Berg reported on 96 patients who completed treatment with follow-up, 93 of whom achieved SVR. The other three patients discontinued treatment due to adverse events that the researchers did not consider related to the drug.

Berg stated that he looks forward to analyzing data on patients from the cohort with decompensated liver disease, those with different treatment experiences, and those who received glecaprevir/pibrentasvir for longer or shorter than recommended, “because it’s interesting to learn day-to-day, in the real world what happened in real practice.”

For more information:

Berg T, et al. GS-007. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.

Disclosure: Berg reports financial connections with AbbVie.

PARIS — Results from a real-world cohort of patients with hepatitis C treated with Mavyret showed a sustained virologic response of 97%, according to an exclusive interview with Thomas Berg, MD, at the International Liver Congress.

“What we observed in our cohort over the year was that we have newly diagnosed patients,” Berg, from the University Hospital Leipzig in Germany, told Healio Gastroenterology and Liver Disease. “Most of them had probably drug-induced transmission of hepatitis C virus, mild disease, and most patients with more advanced disease or with treatment experience were already being treated in our country.”

To date, Berg and colleagues have enrolled 866 patients with HCV and 638 of those have begun treatment with Mavyret (glecaprevir/pibrentasvir, AbbVie). In his presentation, Berg reported on 96 patients who completed treatment with follow-up, 93 of whom achieved SVR. The other three patients discontinued treatment due to adverse events that the researchers did not consider related to the drug.

Berg stated that he looks forward to analyzing data on patients from the cohort with decompensated liver disease, those with different treatment experiences, and those who received glecaprevir/pibrentasvir for longer or shorter than recommended, “because it’s interesting to learn day-to-day, in the real world what happened in real practice.”

For more information:

Berg T, et al. GS-007. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.

Disclosure: Berg reports financial connections with AbbVie.

    See more from International Liver Congress